NASDAQ: CBIO
Crescent Biopharma, Inc.
$16.54
▼ -0.06 (-0.34%)as of 2026-09-01
1-year price · 252 sessions
Key stats
52-week range$16.54
$8.94$26.98
Today
- Open
- 16.43
- Day high
- 17.14
- Day low
- 16.36
- Prev close
- 16.60
- Volume
- 14K
Valuation
- Mkt cap
- $615M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.8
- P/S
- 51.7
Dividend
- Yield
- —
- Per share
- —
Insider & institutional activity · SEC Form 4 / 13F
- ▲Insiders net buying $11.1M over the last 3 months (2 open-market buys, 7 sales)
- 🏛Institutions reducing (13F)
Crescent Biopharma, Inc. (CBIO) is a Healthcare company listed on NASDAQ. The stock is up 22% over the past year. Over the trailing 3 months, insiders filed 2 open-market buys and 7 sales (SEC Form 4).
Crescent Biopharma, Inc. (CBIO) financials & analyst ratings
Fundamentals (TTM)
Margins
Gross margin100.0%
Operating margin-1417.7%
Net margin-1371.5%
FCF margin-1292.8%
Growth & returns
Revenue growth—
Revenue growth (fwd)-94.0%
EPS growth-13.3%
Return on equity-99.8%
Return on assets-89.2%
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
CBIO earnings date, history & EPS estimates
Next earnings
Nov 5, 2026in NaN days
EPS est $-0.67 · Revenue est $357143
Track record
Beat EPS in 6 of 12 quarters
Avg surprise -23.0% (last 4 quarters)
Earnings history
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 30, 2026 | $-0.74 | $-0.74 | -0.6% | — | — |
| Apr 29, 2026 | $-0.85 | $-0.70 | +17.6% | $1M | +180.0% |
| Nov 6, 2025 | $-1.01 | $-1.27 | -25.7% | — | — |
| Jul 31, 2025 | $-2.69 | $-4.93 | -83.3% | — | — |
| May 14, 2025 | $-0.05 | $-0.04 | +20.0% | — | — |
| Feb 13, 2025 | $-0.16 | $-0.11 | +31.3% | $54086 | — |
| Aug 8, 2024 | $-0.17 | $-0.16 | +5.9% | — | — |
| May 9, 2024 | $-0.16 | $-0.17 | -6.3% | — | — |
| Nov 3, 2023 | $-0.14 | $-0.14 | +0.0% | — | — |
| Aug 2, 2023 | $-0.18 | $-0.13 | +27.8% | — | — |
| May 3, 2023 | $-0.17 | $-0.17 | +0.0% | — | — |
| Nov 9, 2022 | $-0.26 | $-0.16 | +38.5% | — | — |
CBIO insider trading activity (SEC Form 4)
Sentiment
89/100
Buys (3m)
2
Sells (3m)
7
Net (3m)
$11.1M
Insiders buying
Insider trades by month Buys Sells
Jun
Jul
Aug
Dec
Jun
Jul
Context3-month price -15.2%Institutions reducing (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 20, 2026 | Fairmount Funds Management LLCdirector, 10 percent owner: | Buy | 525,897 | $0.00 |
| Jul 20, 2026 | Fairmount Funds Management LLCdirector, 10 percent owner: | Buy | 853,450 | $14.50 |
| Jun 23, 2026 | Brumm Joshua Tdirector, officer: Chief Executive Officer | Sell | 42,305 | $17.99 |
| Jun 23, 2026 | McNeill Jonathanofficer: President and COO | Sell | 20,549 | $17.99 |
| Jun 23, 2026 | Im Ellie Eunkyungofficer: Chief Medical Officer | Sell | 1,219 | $17.99 |
| Jun 23, 2026 | Bispham Barbara Harlinofficer: See Remarks | Sell | 1,218 | $17.99 |
| Jun 23, 2026 | Scalzo Richard Williamofficer: Chief Financial Officer | Sell | 1,112 | $17.99 |
| Jun 23, 2026 | Pinkas Janofficer: Chief Scientific Officer | Sell | 1,288 | $17.99 |
| Jun 23, 2026 | Lynch Ryanofficer: See Remarks | Sell | 465 | $17.99 |
| Jun 3, 2026 | Fairmount Funds Management LLCdirector, 10 percent owner: | Grant | 11,050 | $17.01 |
| Jun 3, 2026 | Moran Susandirector | Grant | 11,050 | $17.01 |
| Jun 3, 2026 | Violin Jonathandirector | Grant | 11,050 | $17.01 |
| Jun 3, 2026 | Balcom Alexandradirector | Grant | 11,050 | $17.01 |
| Jun 3, 2026 | Lubner David Charlesdirector | Grant | 11,050 | $17.01 |
| Dec 17, 2025 | McNeill Jonathanofficer: President and COO | Grant | 78,029 | $13.21 |
Source: CBIO SEC Form 4 filings, latest Jul 20, 2026. For informational purposes only — not investment advice.
See the full CBIO insider & 13F page →Track CBIO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free